Impax Completes Patient Enrolment for IPX066

In the study, the primary efficacy parameter is the per cent 'off time' during waking hours based on the patients' Parkinson's disease diaries.

Impax Pharmaceuticals has announced its completion of patient enrolment in a Phase III comparitive study of IPX066 versus immediate-release carbidopa-levodopa and entacapone in subjects with advanced Parkinson's disease.

The randomised, double-blind, two-treatment, two-period crossover study of IPX066, an investigational extended-release capsule formulation of carbidopa-levodopa, enrolled 110 people, 90 of whom were entered into the comparative phase of the study, following which they will be enrolled in a six-month open-label extension phase.

In the study, the primary efficacy parameter is the per cent "off time" during waking hours based on the patients' Parkinson's disease diaries.

The